Zai Lab Limited

Zai Lab reported net product revenue of $105.8 million in the second quarter, up 11% sequentially, and said the business remained commercially profitable. Management did not give quarterly EPS, gross margin, or year-over-year revenue figures in the call. On guidance, the company expects to further stabilize product sales in the second half of the year, with a return to meaningful year-on-year growth in 2027, supported by new product launches, potential NRDL inclusion, and continued demand growth across key brands. Operating expenses are expected to remain broadly stable through the remainder of the year, and cash was $717.5 million at quarter-end.

Samantha Du framed the quarter as an inflection point in Zai Lab’s evolution from a regional business into a global biopharmaceutical company. She emphasized the speed of the pipeline, highlighting Zoci’s move from IND to global pivotal trials in less than 2 years and saying the company is building toward its first U.S. regulatory submission next year. Her tone was confident and long-term oriented, with repeated references to a profitable commercial base plus a growing global innovation engine.

Yajing Chen said the company’s objective is to build on a commercially profitable business while investing with discipline behind innovation. She cited 11% sequential net product revenue growth to $105.8 million, said ZEJULA was steady, VYVGART volumes grew double digits sequentially, XACDURO demand remained strong despite supply constraints, and KarXT’s launch was off to an excellent start. She also said operating expenses should remain broadly stable for the rest of the year and that the company ended the quarter with $717.5 million in cash.

Analysts asked about the profitability timeline, and management replied that profitability should be viewed through the lens of capital allocation: the company is already commercially profitable, but it is choosing to invest in higher-return global programs rather than optimize near-term profit. They also pressed on ZL-1503 differentiation; Rafael Amado said the asset’s pitch is a combination of robust skin clearance, longer dosing interval via YTE modification, and dual IL-13/IL-31 biology, and he said the atopic dermatitis market is underpenetrated rather than winner-take-all. Questions on Zoci combinations focused on dose, data timing, and rationale versus other DLL3/B7-H3 combinations; management said 1.6 mg/kg remains the target dose, combination studies are ongoing, and first readouts are likely next year, toward the end of the second half.